Stock Price & Analysis

Based on the recent market data and analysis, here's a direct assessment of HSIC stock:

The stock shows positive momentum with a 3.6% gain to $79.86 in the latest trading session. Technical indicators suggest a neutral to slightly bullish stance:

Key Technical Levels:

• Fibonacci Resistance: R1 at $78.99, R2 at $79.90
• Fibonacci Support: S1 at $76.05, S2 at $75.14
• Current price is testing the upper resistance levels

Recent Catalysts:

• KKR & Co's significant investment and additional $250 million commitment in January 2025 has provided strong institutional backing
• Stock has outperformed YTD with 11.6% gain compared to S&P 500's 2.2% advance

Analyst Consensus:

• "Moderate Buy" rating from 14 analysts
• 6 Strong Buy, 7 Hold, 1 Strong Sell
• Mean price target: $79.85 (3.4% upside potential)
• Street-high target: $90 (16.5% upside)

Recommendation: SELL

• Stock is approaching key resistance levels
• Currently trading near analyst price targets
• Upcoming earnings report on February 25th creates short-term uncertainty
• Technical indicators suggest overbought conditions

Based on the provided data and recent market analysis, I'll provide a price prediction for HSIC stock in 2025:

Technical Analysis & Price Trends The stock is currently trading at $76.56 in the post-market session, showing mixed signals with:

• Regular market gain: +0.52%
• Post-market decline: -1.35%
• Current trading range: Support at $75.14 (Fibonacci S2) and resistance at $78.99 (Fibonacci R1)

Fundamental Catalysts According to recent analyst reports, HSIC has shown stronger performance in 2025 with:

• YTD gain of 11.6%, outperforming S&P 500's 2.2% advance
• Strategic investment from KKR with additional $250 million commitment
• EPS growth projection of 5.3% to $4.74 for FY2024

Analyst Consensus The current analyst outlook suggests:

• Mean price target: $79.85 (3.4% upside from current levels)
• Street-high target: $90.00 (16.5% upside potential)
• Recent price target upgrade by Barrington to $90 from $82

Based on technical indicators, fundamental catalysts, and analyst consensus, HSIC stock is expected to reach $82-85 range by end of 2025, supported by KKR's strategic investment and operational improvements, though near-term headwinds may create some volatility.

The S1 support level for HSIC Stock is $72.77 ,The R1 resistant level for HSIC Stock is $79.56.

As of the end of day on 2025-02-27, the price of HSIC Stock was $72.15.

The target price for HSIC Stock according to analyst rating is 81.89, with the highest price target at 90.00 and the lowest at 74.00. Analysts have a Hold rating on HSIC Stock overall.

The market cap of HSIC is $9.0B.

Based on the provided data and recent market information, I'll analyze whether HSIC is overvalued through multiple perspectives:

Valuation Metrics:

• Current P/E ratio of 23.98x [Relevant Data] is higher than its historical average over the past year (ranging from 14.66x to 23.98x)
• EV/EBITDA of 13.62x is at the high end of its 52-week range (10.17x to 13.62x)
• Price/Sales ratio of 0.81x and Price/Book ratio of 2.68x are relatively moderate for the healthcare sector

Recent Performance & Fundamentals:

• Net margin has declined from 4.48% to 3.53% year-over-year
• ROE decreased significantly from 15.66% to 11.72%
• Debt-to-Equity ratio increased substantially from 28.06% to 54.81%, indicating higher financial leverage

Market Sentiment:

• According to recent analyst coverage, the stock has a consensus "Moderate Buy" rating with a mean price target of $79.85, suggesting only modest upside potential
• The stock has gained 11.6% YTD in 2025, outperforming the S&P 500's 2.2% advance

Conclusion: HSIC appears moderately overvalued at current levels based on:

1. Elevated earnings multiples compared to historical ranges
2. Deteriorating fundamental metrics
3. Increased financial leverage
4. Limited upside potential based on analyst consensus
5. Recent price appreciation that may have pushed valuations ahead of fundamentals

Henry Schein, Inc. is a solutions company for health care professionals powered by a network of people and technology. The Company operates through two segments: health care distribution, and technology and value-added services. The health care distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, dental specialty products (including implant, orthodontic and endodontic products), diagnostic tests, infection-control products, personal protective equipment products (PPE) and vitamins. The technology and value-added services segment provides software, technology and other value-added services to health care practitioners. It offers dental practice management solutions for dental and medical practitioners. In addition, it offers dentists and physicians a suite of electronic health records and patient communication services.

Based on the provided data and market analysis, here's a projection for HSIC stock price in 2030:

Henry Schein (HSIC) stock is projected to reach $115-120 by 2030, driven by steady growth in its dental and medical distribution segments. The company's strong market position in dental distribution (61% of revenue) and consistent margin expansion through operational efficiency provide a solid foundation for long-term growth. Recent strategic investments, including KKR's additional $250 million commitment, signal confidence in the company's future prospects.

HSIC has a total of 25000 employees.